93102-21-7

Basic information

• Product Name: 2H-Benzimidazol-2-one,1,3-dihydro-5-methyl-,hydrazone(9CI)
• Synonyms: 2H-Benzimidazol-2-one,1,3-dihydro-5-methyl-,hydrazone(9CI)
• CAS NO: 93102-21-7
• Molecular Formula: C₈H₁₀N₄
• Molecular Weight: 0
• Product Categories: BENZIMIDAZOLE
• Mol File: 93102-21-7.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2H-Benzimidazol-2-one,1,3-dihydro-5-methyl-,hydrazone(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Benzimidazol-2-one,1,3-dihydro-5-methyl-,hydrazone(9CI)(93102-21-7)
• EPA Substance Registry System: 2H-Benzimidazol-2-one,1,3-dihydro-5-methyl-,hydrazone(9CI)(93102-21-7)

Safety Data

• Hazardous Substances Data: 93102-21-7(Hazardous Substances Data)

Usage

Chemical Class

Hydrazone derivative

Structure

Derivative of 1,3-dihydro-5-methyl-2H-benzimidazol-2-one

Molecular Weight

Not provided

Heterocyclic Nature

Yes

Biological Activity

Potential biological and pharmaceutical applications

Known Biological Activities of Hydrazones

Antimicrobial
Anticonvulsant
Antitumor

Potential Therapeutic Applications

Treatment of various diseases

Interest in Drug Discovery

Potential as therapeutic agents

Need for Further Research

Uncover full potential and applications

Upstream product

• 5400-75-9 5-methyl-1,3-dihydro-2H-benzimidazol-2-one 
• 496-72-0 4-methyl-1,2-diaminobenzene 
• 4887-94-9 2-chloro-5-methyl-1H-1,3-benzimidazole 

Downstream Products

• 120513-37-3 2-[5-(4-Fluoro-phenyl)-3-methyl-pyrazol-1-yl]-5-methyl-1H-benzoimidazole 
• 1338824-90-0 C₂₅H₂₂N₄O₂S 
• 1338825-01-6 C₂₉H₂₀F₆N₄O₄S 
• 1338824-79-5 C₂₃H₂₀N₄O 
• 1453097-37-4 C₁₉H₁₇ClN₄O 
• 1453097-19-2 4-[(4-chlorophenyl)methyl]-3-methyl-1-(5-methyl-1H-benzimidazol-2-yl)-1H-pyrazol-5-ol 
• 1453097-21-6 4-[(3,4-dichlorophenyl)methyl]-3-methyl-1-(5-methyl-1H-benzimidazol-2-yl)-1H-pyrazol-5-ol 
• 1453097-22-7 C₂₀H₁₇F₃N₄O 
• 1453097-24-9 4-[[4-(1,1-dimethylethyl)phenyl]methyl]-3-methyl-1-(5-methyl-1H-benzimidazol-2-yl)-1H-pyrazol-5-ol 
• 1453097-36-3 C₁₉H₁₇FN₄O 
• 1453097-38-5 C₂₀H₂₀N₄O₂ 
• 1453097-20-5 3-methyl-1-(5-methyl-1H-benzimidazol-2-yl)-4-[(4-phenylphenyl)methyl]-1H-pyrazol-5-ol 
• 1453097-13-6 1-(5-methyl-1H-benzimidazol-2-yl)-3-methyl-4-(phenylmethyl)-1H-pyrazol-5-ol 
• 1453097-57-8 C₁₈H₁₆N₄O 

Relevant articles and documents

NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREFOR

To provide a compound that has excellent oral absorbency and can inhibit Prostate Cancer Antigen-1(PCA-1) enzyme activity.SOLUTION: The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (Ris H,

Design and synthesis of prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors as anti-prostate cancer drugs

A series of 1-aryl-3,4-substituted-1H-pyrazol-5-ol derivatives was synthesized and evaluated as prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors to obtain a novel anti-prostate cancer drug. After modifying 1-(1H-benzimidazol-2-yl)-3,4-dimethyl-1H-pyrazol-5-ol (1), a hit compound found during random screening using a recombinant PCA-1/ALKBH3, 1-(1H-5- methylbenzimidazol-2-yl)-4-benzyl-3-methyl-1H-pyrazol-5-ol (35, HUHS015), was obtained as a potent PCA-1/ALKBH3 inhibitor both in vitro and in vivo. The bioavailability (BA) of 35 was 7.2% in rats after oral administration. As expected, continuously administering 35 significantly suppressed the growth of DU145 cells, which are human hormone-independent prostate cancer cells, in a mouse xenograft model without untoward effects.